This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: Observation TMB-therapuDrug
status: Final
category: Laboratory, Genetics
code: Therapeutic Implication
effective: 2023-02-01
performer: Practitioner Test Dolin
derivedFrom: Observation Mutations/Megabase [# Ratio] in Tumor
component
code: Therapeutic Implication
value: cancer sensitive to pembrolizumab
component
code: Associated phenotype
value: Non-small cell lung cancer
component
code: Medication assessed
value: Pembrolizumab
component
code: Conclusion Text
value: Non-small cell lung cancer with high TMB is sensitive to pembrolizumab